Author (year) | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | (11) | Percent |
|---|
Aludwan [35] | Y | Y | N | U | Y | Y | N | Y | N | U | U | 5/11(45%) |
Paredez [42] | Y | Y | Y | Y | Y | N | N | Y | Y | N | U | 7/11(64%) |
Jia [36] | Y | Y | Y | Y | Y | Y | N | Y | N | Y | U | 8/11(73%) |
Mustafa [37] | Y | Y | Y | U | U | N | N | Y | U | Y | U | 5/11(45%) |
Xiang [38] | Y | Y | Y | Y | Y | N | N | Y | Y | U | U | 7/11(64%) |
Liu [40] | Y | Y | Y | Y | Y | N | N | Y | Y | N | U | 7/11(64%) |
Zhou [41] | Y | Y | Y | Y | Y | Y | N | Y | N | Y | U | 8/11(73%) |
- AHRQ, Agency for Healthcare Research and Quality; Y, Yes; N, No; U, Unclear
- [1] Define the source of information (survey, record review); [2] List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; [3] Indicate time period used for identifying patients; [4] Indicate whether or not subjects were consecutive if not population-based; [5] Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; [6] Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements); [7] Explain any patient exclusions from analysis; [8] Describe how confounding was assessed and/or controlled; [9] If applicable, explain how missing data were handled in the analysis; [10] Summarize patient response rates and completeness of data collection; [11] Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained
